BARD1 and malignant colon neoplasm: Ozden et al. [61] proved that BARD1β sensitizes colon cancer cells to poly PARP-1 inhibition even in an FL BARD1 background, thus suggesting that BARD1β may serve as a future biomarker for assessing the suitability of colon cancers for homologous recombination targeting with PARPi in the treatment of advanced colon cancer.